Unum Therapeutics, a US-based company developing cellular immunotherapies to treat cancer, has raised $12m in a series A round featuring Sanofi-Genzyme BioVentures, the corporate venture capital fund of France-based pharmaceutical company Sanofi.
The round was led by Fidelity Biosciences, the venture capital subsidiary of mutual fund manager Fidelity, and venture capital firm Atlas Ventures.
Unum is developing cancer treatments based on antibody-coupled T-cell receptor (ACTR) technology. The series A cash will support initial clinical studies as it seeks to enhance its technology.
Charles Wilson, president and CEO of Unum Therapeutics, said: “With our series A funding from Fidelity Biosciences, Atlas Venture, and Sanofi-Genzyme BioVentures, we will drive our lead programme into Phase I testing and aim to quickly validate the ACTR approach in the clinic.”